Propranolol treatment ( DrugBank: Propranolol )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 227 | Osler disease | 1 |
227. Osler disease
Clinical trials : 56 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04113187 (ClinicalTrials.gov) | June 23, 2020 | 27/9/2019 | Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | Hereditary Hemorrhagic Telangiectasia;Osler Weber Rendu Disease | Drug: Propranolol treatment;Drug: Placebo | University Hospital, Bordeaux | AMRO-HHT-France - Association Maladie de Rendu-Osler | Completed | 18 Years | N/A | All | 15 | Phase 3 | France |